Literature DB >> 17531172

Antiphospholipid antibody effects on monocytes.

Alisa S Wolberg1.   

Abstract

Although the presence of autoantibodies is known to increase the risk of thrombosis in the antiphospholipid syndrome, the mechanism by which these antibodies exert their effects is poorly understood. Several studies suggest that autoantibody-mediated dysregulation of monocytes is one pathobiologic mechanism of this disease. Recent studies have focused on extra- and intracellular interactions involved in monocyte activation and expression of procoagulant activity. Agents specifically targeting monocyte activation and activity may provide a novel and efficacious approach that is safer than current antithrombotics.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17531172     DOI: 10.1007/s11926-007-0032-z

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.686


  49 in total

1.  Dilazep, an antiplatelet agent, inhibits tissue factor expression in endothelial cells and monocytes.

Authors:  H Deguchi; H Takeya; H Wada; E C Gabazza; N Hayashi; H Urano; K Suzuki
Journal:  Blood       Date:  1997-09-15       Impact factor: 22.113

2.  High affinity binding of beta 2-glycoprotein I to human endothelial cells is mediated by annexin II.

Authors:  K Ma; R Simantov; J C Zhang; R Silverstein; K A Hajjar; K R McCrae
Journal:  J Biol Chem       Date:  2000-05-19       Impact factor: 5.157

3.  Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies.

Authors:  Mariano Vega-Ostertag; Katherine Casper; Robert Swerlick; Dardo Ferrara; E Nigel Harris; Silvia S Pierangeli
Journal:  Arthritis Rheum       Date:  2005-05

4.  Antithrombotic effects of recombinant human, active site-blocked factor VIIa in a rabbit model of recurrent arterial thrombosis.

Authors:  P Golino; M Ragni; P Cirillo; D D'Andrea; A Scognamiglio; A Ravera; C Buono; M Ezban; N Corcione; F Vigorito; M Condorelli; M Chiariello
Journal:  Circ Res       Date:  1998 Jan 9-23       Impact factor: 17.367

5.  Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men.

Authors:  O Vaarala; M Mänttäri; V Manninen; L Tenkanen; M Puurunen; K Aho; T Palosuo
Journal:  Circulation       Date:  1995-01-01       Impact factor: 29.690

6.  Enhanced monocyte expression of tissue factor by oxidative stress in patients with antiphospholipid antibodies: effect of antioxidant treatment.

Authors:  D Ferro; M Saliola; P L Meroni; G Valesini; C Caroselli; D Praticò; G A Fitzgerald; Y Shoenfeld; F Violi
Journal:  J Thromb Haemost       Date:  2003-03       Impact factor: 5.824

7.  Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome.

Authors:  Gabriela Cesarman-Maus; Nina P Ríos-Luna; Arunkumar B Deora; Bihui Huang; Rosario Villa; Maria del Carmen Cravioto; Donato Alarcón-Segovia; Jorge Sánchez-Guerrero; Katherine A Hajjar
Journal:  Blood       Date:  2006-02-21       Impact factor: 22.113

8.  Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies.

Authors:  A Kornberg; M Blank; S Kaufman; Y Shoenfeld
Journal:  J Immunol       Date:  1994-08-01       Impact factor: 5.422

9.  The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-beta2Glycoprotein I antibodies.

Authors:  Miyuki Bohgaki; Tatsuya Atsumi; Yumi Yamashita; Shinsuke Yasuda; Yoshie Sakai; Akira Furusaki; Toshiyuki Bohgaki; Olga Amengual; Yoshiharu Amasaki; Takao Koike
Journal:  Int Immunol       Date:  2004-10-05       Impact factor: 4.823

10.  Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep.

Authors:  Hong Zhou; Alisa S Wolberg; Robert A S Roubey
Journal:  Blood       Date:  2004-06-29       Impact factor: 22.113

View more
  2 in total

1.  Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers.

Authors:  Jacob H Rand; Xiao-Xuan Wu; Anthony S Quinn; Pojen P Chen; James J Hathcock; Douglas J Taatjes
Journal:  Blood       Date:  2008-06-24       Impact factor: 22.113

2.  TIMELESS is a key gene mediating thrombogenesis in COVID-19 and antiphospholipid syndrome.

Authors:  Wenjing Zhang; Longjiang Di; Zhongshuang Liu; Qi Sun; Yan Wu; Nuan Wang; Meili Jin; Lingling Gao; Mengyu Zhang
Journal:  Sci Rep       Date:  2022-10-14       Impact factor: 4.996

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.